Search results
Results From The WOW.Com Content Network
Rucaparib, sold under the brand ... The studies for these two trials are still going on and the estimated dates for the first results are range between 2019 and 2022 ...
Decitabine/cedazuridine was approved for medical use in the United States and Canada in July 2020, [7] [8] [9] [12] and in the European Union in September 2023. [6]The U.S. Food and Drug Administration (FDA) granted the application of decitabine combined with cedazuridine priority review and orphan drug designation.
Earlier this month, Clovis Oncology Inc (NASDAQ: CLVS) had a Type A meeting with the FDA to discuss its plans for a supplemental marketing application for Rubraca (Rucaparib) as a first-line ...
Iniparib (BSI 201, developed by Sanofi) was determined in 2012 not to be a true PARP inhibitor [38] [39] and failed trial for triple negative breast cancer. [37] In 2013 Sanofi disclosed that iniparib failed to help squamous cell lung cancer patients in a phase III trial, prompting the company to end research into the once-promising compound.
For premium support please call: 800-290-4726 more ways to reach us
[24] [25] The trial was completed in August 2021 and results have become available in March 2022. [24] Another phase II/III trial for APDS/PASLI that serves as an extension study (NCT02859727) is still ongoing and results are expected for October 2026. [26] The FDA has approved leniolisib on March 24, 2023.
On April 6, 1997, 25-year-old Gregory "Greg" Philip Malnory (July 18, 1971 – April 6, 1997) and his 26-year-old wife Kimberly "Kim" Ann Malnory (née Parkinson; November 9, 1970 – April 6, 1997) were murdered by James Dennis Ford (born July 23, 1960) at South Florida Sod Farm in Charlotte County, Florida, after Ford lured the couple to the farm under the pretense of a fishing trip.
Lurbinectedin was approved for medical use in the United States in June 2020. [9] [5] [6] [7] [10]Efficacy was demonstrated in the PM1183-B-005-14 trial (Study B-005; NCT02454972), a multicenter open-label, multi-cohort study enrolling 105 participants with metastatic SCLC who had disease progression on or after platinum-based chemotherapy.